Acquisition brings Pharmacovigilance Expansion Opportunities in Ireland and Europe

Technical services and regulatory consulting group Diamond Pharma Services has acquired Dublin-based PharmaCentral, a pharmacovigilance services and medical affairs business.

The move forms part of Diamond’s growth strategy of its pharmacovigilance division, which has achieved a compound annual growth rate (CAGR) in revenues of 27% over the last three years, adding further support in specialist areas such as gene and cell therapies.

David Boyd, Managing Director, Diamond PV Services Ltd, said: “We have seen strong organic growth over the last three years, which has driven us to evaluate our resources, including our in-house expertise, processes and systems. This acquisition will help support the next phase of growth, representing a step change in our senior team. Having worked closely with PharmaCentral over the past year I am confident that they share our culture of flexibility, quality and accessibility, and am hugely excited that they are joining Diamond to deliver our shared vision of helping our clients manage their regulatory responsibilities in a constantly evolving environment.”

Catherine Kenny, Co-founder of PharmaCentral LLP, commented: “This is an incredibly meaningful milestone for PharmaCentral. The cultural fit we have found between the two businesses, and our shared views on the growth areas within pharmacovigilance have created synergistic opportunities for both companies. PharmaCentral has spent a number of years building strong customer relationships and a reputation for quality. Together we will capitalise on those strengths to significantly increase our capabilities and service offerings. The PharmaCentral team is excited to join Diamond Pharma Services and we look forward to the future.”